- Home
- IREN vs BBIO Comparison
IREN vs BBIO Comparison
Compare IREN & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IREN | BBIO |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3B | 12.5B |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | IREN | BBIO |
|---|---|---|
| Price | $44.97 | $74.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 19 |
| Target Price | $72.56 | ★ $74.79 |
| AVG Volume (30 Days) | ★ 43.2M | 2.2M |
| Earning Date | 11-06-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.99 | N/A |
| Revenue | ★ $688,554,000.00 | $353,780,000.00 |
| Revenue This Year | $138.51 | $128.44 |
| Revenue Next Year | $116.49 | $76.14 |
| P/E Ratio | $22.11 | ★ N/A |
| Revenue Growth | ★ 234.97 | 62.46 |
| 52 Week Low | $5.13 | $25.34 |
| 52 Week High | $76.87 | $74.34 |
Technical Indicators
Market Signals| Indicator | IREN | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 43.02 | 75.23 |
| Support Level | $39.93 | $71.16 |
| Resistance Level | $51.50 | $67.71 |
| Average True Range (ATR) | 5.12 | 2.58 |
| MACD | -0.55 | 0.33 |
| Stochastic Oscillator | 37.90 | 94.48 |
Price Performance
Historical ComparisonAbout IREN Iris Energy Limited
IREN Ltd is engaged in data center business powering the future of Bitcoin, AI and beyond utilizing renewable energy. Bitcoin mining operations generate revenue by earning Bitcoin through a combination of Block rewards and transaction fees from the operation of its Bitcoin miners and exchanging these Bitcoin for fiat currencies such as USD or CAD.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.